Patrick Thornton
A5077471584- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Maternal and Perinatal Health Interventions
- Advanced Breast Cancer Therapies
- Maternal and fetal healthcare
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Neonatal Respiratory Health Research
- Global Maternal and Child Health
- Eosinophilic Disorders and Syndromes
- Cancer-related Molecular Pathways
- Global Health Workforce Issues
- Acute Lymphoblastic Leukemia research
- Neonatal and fetal brain pathology
- Assisted Reproductive Technology and Twin Pregnancy
- Acute Myeloid Leukemia Research
- Urinary Bladder and Prostate Research
- Neuroscience of respiration and sleep
- Venous Thromboembolism Diagnosis and Management
- Monoclonal and Polyclonal Antibodies Research
- Sexual function and dysfunction studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pregnancy-related medical research
- Delphi Technique in Research
Beaumont Hospital
2014-2024
Cancer Trials Ireland
2023-2024
University of Illinois Chicago
2019-2023
Illinois Department of Children and Family Services
2019
Cook Children's Medical Center
2019
Connolly Hospital Blanchardstown
2006-2018
Hudson Institute
2017
John Wiley & Sons (United States)
2017
Botsford Hospital
2014
Beaumont Hospital, Dearborn
2014
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy adverse cytogenetic abnormalities are associated poor outcome. We evaluated the efficacy ibrutinib, covalent inhibitor Bruton's tyrosine kinase, in at risk for
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall (OS) and response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients high-risk prognostic factors. We report updated results from these traditionally chemotherapy resistant genomic subgroups at a median follow-up of 19 months. Mutations were detected by Foundation One Heme Panel. Baseline mutations arm included TP53 (51%), SF3B1 (31%), NOTCH1 (28%), ATM (19%) BIRC3...
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
In the primary analysis report of GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates progression-free survival compared with chemoimmunotherapy in patients previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons different venetoclax-based combinations are available.
T-prolymphocytic leukemia (T-PLL) is an aggressive malignancy of mature T cells refractory to conventional chemotherapy, with a median survival duration 7.5 months. We report here promising results the use genetically reshaped human CD52 antibody, CAMPATH-1H.Fifteen patients T-PLL, most whom had received purine analog deoxycoformycin (DCF), were treated CAMPATH-1H. Results compared those 25 DCF.Major responses occurred in 11 (73%) CAMPATH-1H 40% DCF. Complete remissions (CRs) documented nine...
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on immunoglobulin heavy variable (IGHV) somatic hypermutation (SHM) status. In this study, we assessed nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) pre-treatment samples from 4580 CLL, using time-to-first-treatment (TTFT) as primary end-point relation to IGHV SHM Mutations were detected 1588 (34.7%)...
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, 27/1715 (1.6%) cases referred investigation eosinophilia. Of 27 mutated cases, working diagnosis hypereosinophilic syndrome (HES; n = 7) or myeloid neoplasm with (n 20) had been made prior to detection N642H. Myeloid panel analysis median 2 additional genes (range 0–4) 4...
is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of
To evaluate self-reported sensory pain scores of women with generalized vulvodynia (GV) and provoked vestibulodynia (PVD), characterize phenotypes, assess feasibility using the Internet for recruitment data collection among vulvodynia.Descriptive online survey. Data collected an survey accessed via a link on National Vulvodynia Association web site. Convenience sample, 60 aged 18 to 45 years (mean = 32.7 ± 5.5); 50 white, 2 black/African American, 4 Hispanic/Latino, Native American/Alaskan...
We assessed the role of human CD52 antibody (Campath-1H) in six patients with chronic lymphocytic leukaemia (CLL) treated to maximal response purine analogues (fludarabine/deoxycoformycin) whom persistent leukaemic infiltration blood and bone marrow had precluded autologous stem cell transplantation. Five achieved haematological histological complete remission following Campath-1H one minimal focal residual CLL a trephine biopsy. Autologous transplantation was performed two without...
Introduction High rates of cesarean birth are a significant health care quality issue, and centers have shown potential to reduce birth. Measuring this is complicated by lack randomized trials limited observational comparisons. Cesarean vary provider type, setting, clinical nonclinical characteristics women, but our understanding these dynamics incomplete. Methods We sought isolate labor setting from other risk factors in order assess the effect on odds generated low‐risk cohorts admitted...
Large granular lymphocyte leukemia (T-LGL) is an indolent T lymphoproliferative disorder that was difficult to diagnose with certainty until clonality testing of the cell receptor gene became routinely available. We studied natural history and response treatment in 25 consecutive patients T-LGL diagnosed between 2004 2008 which diagnosis confirmed by molecular analysis, define effective algorithm. The median age at 61 years (range 27–78), a male female ratio 1:1.8 presenting features fatigue...
We treated 14 patients with advanced, resistant chronic lymphocytic leukaemia (CLL) including three >10% prolymphocytes (CLL/PL) high dose methyl prednisolone (HDMP). All had stage C CLL or bulky B disease. There were 11 males and 3 females a median age of 58.5 years (range: 49–69). Six out eleven partial response as defined by the NCI guidelines, no patient complete remission. The mean duration PR was 19.6 months 8 (range 6-78). Seven have died 5 non-responders. None CLL/PL measurable...